Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: Role of cytosolic phospholipase A2-α and kinase signaling pathways

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 2-3, 2010, Pages 131-139

  Gentile, Luciana B ^a,b   Piva, Bruno ^b   Capizzani, Bianca C ^b   Furlaneto, Luiz G B ^a   Moreira, Luciana S ^a   Zamith Miranda, Daniel ^b   Diaz, Bruno L ^b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Colon Cancer; COX 2; CPLA2 ; Hypertonic stress; MAP kinase; PGE2

Indexed keywords

ARACHIDONIC ACID; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE INHIBITOR; PROSTAGLANDIN E2; SECRETORY PHOSPHOLIPASE A2; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL STIMULATION; CELL STRAIN CACO 2; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPEROSMOTIC STRESS; LIPID METABOLISM; MEDIATOR RELEASE; MODULATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

CACO-2 CELLS; CYCLOOXYGENASE 2; DINOPROSTONE; GROUP IV PHOSPHOLIPASES A2; HUMANS; HYPERTONIC SOLUTIONS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 77951665998     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.11.005     Document Type: Article

References (58)

1. Fukuda R., Kelly B., Semenza G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 Is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63:2330.
2. Sheng H., Shao J., Washington M.K., DuBois R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 2001, 276:18075-18081.
3. Tomozawa S., Tsuno N.H., Sunami E., Hatano K., Kitayama J., Osada T., Saito S., Tsuruo T., Shibata Y., Nagawa H. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer 2000, 83:324-328.
4. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S.K., DuBois R.N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 2006, 203:941-951.
5. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-Axin-{beta}-catenin signaling axis. Science 2005, 310:1504-1510.
6. Δ716 knockout mice. Nat. Med. 2001, 7:1048-1051.
7. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., Sugimura T., Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999, 59:5093-5096.
8. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
9. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55:3785-3789.
10. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J., Beauchamp R.D., DuBois R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997, 99:2254-2259.
11. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69(145-82):145-182.
12. Yoshimatsu K., Golijanin D., Paty P.B., Soslow R.A., Jakobsson P.J., DeLellis R.A., Subbaramaiah K., Dannenberg A.J. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 2001, 7:3971-3976.
13. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 1998, 90:1609-1620.
14. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
15. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
16. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
17. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352:1092-1102.
18. Diaz B.L., Arm J.P. Phospholipase A(2). Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:87-97.
19. Schaloske R.H., Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta (BBA) - Molec. Cell Biol. Lipids 2006, 1761:1246-1259.
20. Ghosh M., Tucker D.E., Burchett S.A., Leslie C.C. Properties of the Group IV phospholipase A(2) family. Prog. Lipid. Res. 2006, 45:487-510.
21. Durstin M., Durstin S., Molski T.F.P., Becker E.L., Sha'afi R.I. Cytoplasmic phospholipase A2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase. PNAS 1994, 91:3142-3146.
22. Lin L.L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., Davis R.J. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278.
23. Nemenoff R.A., Winitz S., Qian N.X., Van Putten V., Johnson G.L., Heasley L.E. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J. Biol. Chem. 1993, 268:1960-1964.
24. Gijon M.A., Spencer D.M., Siddiqi A.R., Bonventre J.V., Leslie C.C. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J. Biol. Chem. 2000, 275:20146-20156.
25. Takaku K., Sonoshita M., Sasaki N., Uozumi N., Doi Y., Shimizu T., Taketo M.M. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 2000, 275:34013-34016.
26. Hong K.H., Bonventre J.C., O'Leary E., Bonventre J.V., Lander E.S. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98:3935-3939.
27. Panel V., Boelle P.Y., Ayala-Sanmartin J., Jouniaux A.M., Hamelin R., Masliah J., Trugnan G., Flejou J.F., Wendum D. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006, 243:255-263.
28. Dong M., Guda K., Nambiar P.R., Rezaie A., Belinsky G.S., Lambeau G., Giardina C., Rosenberg D.W. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003, 24:307-315.
29. Ilsley J.N.M., Nakanishi M., Flynn C., Belinsky G.S., De Guise S., Adib J.N., Dobrowsky R.T., Bonventre J.V., Rosenberg D.W. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res. 2005, 65:2636-2643.
30. Cao Y., Pearman A.T., Zimmerman G.A., McIntyre T.M., Prescott S.M. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl. Acad. Sci. USA 2000, 97:11280-11285.
31. Brash A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 2001, 107:1339-1345.
32. Taketo M.M., Sonoshita M. Phospolipase A2 and apoptosis. Biochim. Biophys. Acta 2002, 1585:72-76.
33. Levine L.A.W.R. Does the release of arachidonic acid from cells play a role in cancer chemoprevention?. FASEB J. 2003, 17:800-802.
34. Nakanishi M., Rosenberg D.W. Roles of cPLA2[alpha] and arachidonic acid in cancer. Biochim. Biophys. Acta (BBA) - Molec. Cell Biol. Lipids 1761, 1335-1343:2006.
35. Ding L.A., Li J.S. Gut in diseases: physiological elements and their clinical significance. World J. Gastroenterol. 2003, 9:2385-2389.
36. Naftalin R.J., Pedley K.C. Video enhanced imaging of the fluorescent Na+ probe SBFI indicates that colonic crypts absorb fluid by generating a hypertonic interstitial fluid. FEBS Lett. 1990, 260:187-194.
37. Powell D.W. Dogma destroyed: colonic crypts absorb. J. Clin. Invest. 1995, 96:2102-2103.
38. Thiagarajah J.R., Jayaraman S., Naftalin R.J., Verkman A.S. In vivo fluorescence measurement of Na(+) concentration in the pericryptal space of mouse descending colon. Am. J. Physiol. Cell Physiol. 2001, 281:C1898-C1903.
39. Yang T., Zhang A., Honeggar M., Kohan D.E., Mizel D., Sanders K., Hoidal J.R., Briggs J.P., Schnermann J.B. Hypertonic Induction of COX-2 in collecting duct cells by reactive oxygen species of mitochondrial origin. J. Biol. Chem. 2005, 280:34966-34973.
40. Yang T., Huang Y., Heasley L.E., Berl T., Schnermann J.B., Briggs J.P. MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells. J. Biol. Chem. 2000, 275:23281-23286.
41. Arbabi S., Rosengart M.R., Garcia I., Jelacic S., Maier R.V. Epithelial cyclooxygenase-2 expression: a model for pathogenesis of colon cancer. J. Surg. Res. 2001, 97:60-64.
42. Lim W.C., Park M., Bahn J.J., Inoue H., Lee Y.J. Hypertonic sodium chloride induction of cyclooxygenase-2 occurs independently of NF-[kappa]B and is inhibited by the glucocorticoid receptor in A549 cells. FEBS Lett. 2005, 579:5430-5436.
43. Galcheva-Gargova Z., Derijard B., Wu I.H., Davis R.J. An osmosensing signal transduction pathway in mammalian cells. Science 1994, 265:806-808.
44. Han J., Lee J.D., Bibbs L., Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265:808-811.
45. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
46. Rennefahrt U., Janakiraman M., Ollinger R., Troppmair J. Stress kinase signaling in cancer: fact or fiction?. Cancer Lett. 2005, 217:1-9.
47. Hardwick J.C., van den Brink G.R., Offerhaus G.J., van Deventer S.J., Peppelenbosch M.P. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001, 20:819-827.
48. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6:322-327.
49. Seno K., Okuno T., Nishi K., Murakami Y., Watanabe F., Matsuura T., Wada M., Fujii Y., Yamada M., Ogawa T., Okada T., Hashizume H., Kii M., Hara S., Hagishita S., Nakamoto S., Yamada K., Chikazawa Y., Ueno M., Teshirogi I., Ono T., Ohtani M. Pyrrolidine Inhibitors of Human Cytosolic Phospholipase A2. J. Med. Chem. 2000, 43:1041-1044.
50. Fujishima H., Sanchez Mejia R.O., Bingham C.O., Lam B.K., Sapirstein A., Bonventre J.V., Austen K.F., Arm J.P. Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc. Natl. Acad. Sci. USA 1999, 96:4803-4807.
51. Sapirstein A., Saito H., Texel S.J., Samad T.A., O'Leary E., Bonventre J.V. Cytosolic phospholipase A2{alpha} regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1774-R1782.
52. Reinehr R., Schliess F., Haussinger D. Hyperosmolarity and CD95L trigger CD95/EGFR association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB J. 2003, 17:731-733.
53. Margolis B.L., Holub B.J., Troyer D.A., Skorecki K.L. Epidermal growth factor stimulates phospholipase A2 in vasopressin-treated rat glomerular mesangial cells. Biochem. J. 1988, 256:469-474.
54. Balsinde J., Balboa M.A., Insel P.A., Dennis E.A. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 1999, 39:175-189.
55. Mounier C.M., Ghomashchi F., Lindsay M.R., James S., Singer A.G., Parton R.G., Gelb M.H. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 Occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-{alpha}. J. Biol. Chem. 2004, 279:25024-25038.
56. Murakami M., Kuwata H., Amakasu Y., Shimbara S., Nakatani Y., Atsumi G., Kudo I. Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J. Biol. Chem. 1997, 272:19891-19897.
57. Moreira L.S., Piva B., Gentile L.B., Mesquita-Santos F.P., D'Avila H., Maya-Monteiro C.M., Bozza P.T., Bandeira-Melo C., Diaz B.L. Cytosolic phospholipase A2-driven PGE2 synthesis within unsaturated fatty acids-induced lipid bodies of epithelial cells. Biochim. Biophys. Acta (BBA) - Molec. Cell Biol. Lipids 1791, 156-165:2009.
58. Accioly M.T., Pacheco P., Maya-Monteiro C.M., Carrossini N., Robbs B.K., Oliveira S.S., Kaufmann C., Morgado-Diaz J.A., Bozza P.T., Viola J.P.B. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res. 2008, 68:1732-1740.